Rezolute, Inc.

NasdaqCM RZLT

Rezolute, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -62.80 M

Rezolute, Inc. Operating Cash Flow is USD -62.80 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -32.27% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Rezolute, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -47.48 M, a -16.18% change year over year.
Rezolute, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -40.86 M, a -75.90% change year over year.
Rezolute, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -23.23 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: RZLT

Rezolute, Inc.

CEO	Mr. Nevan Charles Elam J.D.
IPO Date	Jan. 14, 2013
Location	United States
Headquarters	201 Redwood Shores Parkway
Employees	59
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Key trends

Past 5 years